Serum Adiponectin Levels in Advanced-Stage Parkinson's Disease Patients
Patients with advanced Parkinson's disease (PD) experience body weight loss and reductions in the most common cardiovascular risk factors. At present, the pathogenetic mechanisms involved have not been elucidated. Increased serum concentrations of adiponectin, which possesses antiatherogenic an...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Parkinson's Disease |
| Online Access: | http://dx.doi.org/10.4061/2011/624764 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561864644493312 |
|---|---|
| author | Erica Cassani Raffaella Cancello Ferruccio Cavanna Sabrina Maestrini Anna Maria Di Blasio Antonio Liuzzi Gianni Pezzoli Michela Barichella |
| author_facet | Erica Cassani Raffaella Cancello Ferruccio Cavanna Sabrina Maestrini Anna Maria Di Blasio Antonio Liuzzi Gianni Pezzoli Michela Barichella |
| author_sort | Erica Cassani |
| collection | DOAJ |
| description | Patients with advanced Parkinson's disease (PD) experience body weight loss and reductions in the most common cardiovascular risk factors. At present, the pathogenetic mechanisms involved have not been elucidated. Increased serum concentrations of adiponectin, which possesses antiatherogenic and anti-inflammatory properties, are associated with a reduction in cardiovascular risk. The objective of this study was to determine adiponectin serum concentrations in PD patients. Thirty PD patients underwent a full nutritional status assessment, including the determination of adiponectin serum concentrations. Mean ± SD adiponectin concentrations were 9.59 ± 5.9 μg/mL (interquartile range: 5.92–12.9 μg/mL). In PD patients, adiponectin serum levels were similar to those in normal-weight, healthy, young subjects and significantly higher than that in an aged-matched group of morbidly obese subjects. Further studies are warranted to establish the role of adiponectin in the management of PD patients. |
| format | Article |
| id | doaj-art-a8d89e8ce09d43f18a577a2e04f09e3a |
| institution | Kabale University |
| issn | 2042-0080 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Parkinson's Disease |
| spelling | doaj-art-a8d89e8ce09d43f18a577a2e04f09e3a2025-02-03T01:24:07ZengWileyParkinson's Disease2042-00802011-01-01201110.4061/2011/624764624764Serum Adiponectin Levels in Advanced-Stage Parkinson's Disease PatientsErica Cassani0Raffaella Cancello1Ferruccio Cavanna2Sabrina Maestrini3Anna Maria Di Blasio4Antonio Liuzzi5Gianni Pezzoli6Michela Barichella7Parkinson Institute, Istituti Clinici di Perfezionamento (ICP), via Bignami 1, 20126 Milan, ItalyParkinson Institute, Istituti Clinici di Perfezionamento (ICP), via Bignami 1, 20126 Milan, ItalyParkinson Institute, Istituti Clinici di Perfezionamento (ICP), via Bignami 1, 20126 Milan, ItalyIstituto Auxologico Italiano, via Zucchi 18, 20095 Cusano Milanino, Milan, ItalyIstituto Auxologico Italiano, via Zucchi 18, 20095 Cusano Milanino, Milan, ItalyIstituto Auxologico Italiano, via Zucchi 18, 20095 Cusano Milanino, Milan, ItalyParkinson Institute, Istituti Clinici di Perfezionamento (ICP), via Bignami 1, 20126 Milan, ItalyParkinson Institute, Istituti Clinici di Perfezionamento (ICP), via Bignami 1, 20126 Milan, ItalyPatients with advanced Parkinson's disease (PD) experience body weight loss and reductions in the most common cardiovascular risk factors. At present, the pathogenetic mechanisms involved have not been elucidated. Increased serum concentrations of adiponectin, which possesses antiatherogenic and anti-inflammatory properties, are associated with a reduction in cardiovascular risk. The objective of this study was to determine adiponectin serum concentrations in PD patients. Thirty PD patients underwent a full nutritional status assessment, including the determination of adiponectin serum concentrations. Mean ± SD adiponectin concentrations were 9.59 ± 5.9 μg/mL (interquartile range: 5.92–12.9 μg/mL). In PD patients, adiponectin serum levels were similar to those in normal-weight, healthy, young subjects and significantly higher than that in an aged-matched group of morbidly obese subjects. Further studies are warranted to establish the role of adiponectin in the management of PD patients.http://dx.doi.org/10.4061/2011/624764 |
| spellingShingle | Erica Cassani Raffaella Cancello Ferruccio Cavanna Sabrina Maestrini Anna Maria Di Blasio Antonio Liuzzi Gianni Pezzoli Michela Barichella Serum Adiponectin Levels in Advanced-Stage Parkinson's Disease Patients Parkinson's Disease |
| title | Serum Adiponectin Levels in Advanced-Stage Parkinson's Disease Patients |
| title_full | Serum Adiponectin Levels in Advanced-Stage Parkinson's Disease Patients |
| title_fullStr | Serum Adiponectin Levels in Advanced-Stage Parkinson's Disease Patients |
| title_full_unstemmed | Serum Adiponectin Levels in Advanced-Stage Parkinson's Disease Patients |
| title_short | Serum Adiponectin Levels in Advanced-Stage Parkinson's Disease Patients |
| title_sort | serum adiponectin levels in advanced stage parkinson s disease patients |
| url | http://dx.doi.org/10.4061/2011/624764 |
| work_keys_str_mv | AT ericacassani serumadiponectinlevelsinadvancedstageparkinsonsdiseasepatients AT raffaellacancello serumadiponectinlevelsinadvancedstageparkinsonsdiseasepatients AT ferrucciocavanna serumadiponectinlevelsinadvancedstageparkinsonsdiseasepatients AT sabrinamaestrini serumadiponectinlevelsinadvancedstageparkinsonsdiseasepatients AT annamariadiblasio serumadiponectinlevelsinadvancedstageparkinsonsdiseasepatients AT antonioliuzzi serumadiponectinlevelsinadvancedstageparkinsonsdiseasepatients AT giannipezzoli serumadiponectinlevelsinadvancedstageparkinsonsdiseasepatients AT michelabarichella serumadiponectinlevelsinadvancedstageparkinsonsdiseasepatients |